Webso – webcultura 3.0

Ad Media Traders – 24/7 Automatic Advertising Revenue Stream Distribution Network Paid To You Without Even Lifting a Finger! Just Login, Upgrade and Collect Your Cash! Become a strategic partner in profit with our collective media ad trading network and reap structured hourly rewards commensurate with the funds you place at our disposal! Now let’s get started right now making instant profits, all you need to do is just complete the short registration form and you will be well on your way to earning hourly profits 24 hours a day, 7 days a week! It just never stops!

Fonte:
Links for 2011-06-26 [Digg]

Stock in focus today 7/21/09: INCY (NASDAQ) up 12% : Incyte Reaches Agreement with FDA on a Special Protocol Assessment for INCB18424 in Myelofibrosis SPPI (NASDAQ) up 4%: FDA Designates Fast Track Status for Apaziquone (EOquin®) for Bladder Cancer STAA (NASDAQ) up 7%: Review of STAAR’s application for the Visian Toric Implantable Collamer Lens by FDA to resume NGSX (nasdaq) following uptrend, up 5% to 7,7 usd We sold at open IDIX (NASDAQ), published study results for IDX 184 which was not as good as hoped TICKER                       BUY AREA      QUOTE NOW     POSITION            DRIVER IDIX (NASDAQ)        USD  4,44            4,2 SOLD(-5%) SNTS (NASDAQ)     USD   2,81              3      LONG TERM    FDA REVIEW Zegerid BY DECEMBER BFRM (NASDAQ)        USD   2,85           2            LONG TERM OVERSOLD CONDITIONS OCLS (NASDAQ) USD 2,85     2,7          LONG TERM    MORE UPSIDE TRGT (NASDAQ) USD 5,5          8,3  STRONG BUY     Targacept’s TC-5214 results OREX (NASDAQ) USD 5,35     6,45 SOLD(+20%)   FOLD (NASADQ) USD 10           10,4  LONG TERM     PLICERA, AMIGAL STRONG CONSENSUS SOMX (NASDAQ) USD 1,10       1,38   SOLD (+25%)     DDSS (NASDAQ)  USD 2,65    1,9     SHORT TERM   TRAZODONE FDA PDUFA 7/18/09 XNPT (NASDAQ)  USD 21,85      20,3    LONG TERM    XP19986  POSITIVE TRIAL 6/30/09 VNDA (NASDAQ) 12,1                 12,7        REBUYING      FANAT APPROVED 5/6/09 CYTR (NASDAQ)   USD 1,02      1,2        LONG TERM    STRONG CONSENSUS  JAZZ (NASDAQ)    USD 4,95     4       LONG TERM         STRONG CONSENSUS PARD (NASDAQ)    USD 5          5,9     PROFIT TAKING (+18%)       PARD (NASDAQ) USD 6,6 rebought 7/2    7,1  LONG TERM       STRONG CONSENSUS INCY (NASDAQ) USD 3,5         4,5    LONG TERM            STRONG CONSENSUS   ISTA (NASDAQ) USD 4,1         4,5       LONG TERM          BEPREVE FDA PDUFA  9/12/09 JAV (AMEX)      USD 1,3          1,6       LONG TERM         STRONG CONSENSUS  SLXP (NASDAQ) USD 9,9        11,15  LONG TERM  STRONG CONSENSUS FDA PDUFA 9/9/09 MAPP (NASDAQ) USD 11,3       10,4  REBUYING LONG TERM STRONG CONSENSUS   ARYX (NASDAQ) USD            4,5       SOLD 2,5 (-45%) ARRY (NASDAQ) USD 3,1      3,2    LONG TERM          CLINICAL TRIAL 7/8/09 GTXI (NASDAQ)   USD 9,5      8,7     LONG TERM         FDA PDUFA 10/30/09 UTHR (NASDAQ) USD 84         85,7  LONG TERM        FDA PDUFA 7/30/09 NGSX (NASDAQ) USD 6,4      7,7  LONG TERM        FDA PDUFA 8/16/09 VICL (NASDAQ)  USD 3             2,7    LONG TERM      SWINE FLU STAA (NASDAQ)  USD 3,3        2,4 LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH (NASDAQ)  7,9               7,7   LONG TERM          FDA PDUFA 9/24/09 AMAG (NASDAQ) 52,8        50,2  LONG TERM        FDA APPROVES FERAHEME 6/30/09 XOMA (NASDAQ) 1,2    0,78  LONG TERM  OVERSOLD HEB (AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB (AMEX) was rebought after 100% gain (see old posts) MRNA (NASDAQ)  3,3            1,5      LONG TERM      OVERSOLD RIGL (NASDAQ) USD 10           14,5     LONG TERM     STRONG CONSENSUS MITI (NASDAQ) USD 6              5,05       LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3         7,95    SOLD(-4%)      SVNT (NASDAQ) USD 7,10        13       SOLD(+90%) NPSP (NASDAQ) 3,1 USD        4,75     SOLD(+50%) SCLN (NASDAQ) 2,25 USD        2,7     SOLD (+20%)  LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD  (posts from 5/26)  PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)  PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD         9,6  LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,39 SOLD (-35%) ANPI (NASDAQ) 2 USD           1,39 SOLD(-30%) MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)  LTERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD      11,3   LONG TERM   STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD     2,4       LONG TERM  CLINICAL DATA  3 Q. ACOR (NASDAQ) 24 USD   23,2   LONG TERM FAMPRIDINE-SR, FDA PDUFA 10/22/09 BDSI (NASDAQ)                           PROFIT TAKED 6,3  (+18%)   BDSI (NASDAQ)  6,6 rebought   5,4     SHORT TERM    ONSOLIS APPROVED BY FDA DNDN (NASDAQ)   22 USD (see old post 4/27) 23,1  LONG TERM  PROVENGE SPPI (NASDAQ)  4 USD (see ols post 5/12)    6/12 PROFIT TAKING (+35%) SPPI (NASDAQ)  5,85 USD         7,4     PROFIT TAKING(+28%)   SPPI (NASDAQ)  6,5 USD rebought 7/2  6,1  LT  ZEVALIN FDA PDUFA  09/07/09 FUSILEV PDUFA 08/10/09

Fonte:
Trading-news Biopharma Stock List Update: Incy, Sppi, Staa

In red positive intraday performances, we signal: HITK (NASDAQ) at 14 usd   RIMM(NASDAQ) in an uptrend, now approching 75 usd AGN (NASDAQ) approching 50 usd We are selling SAY (NYSE) at 4,8 usd with 30% gain MOV (NYSE) approching 12 usd   TICKER            BUY AREA          QUOTE NOW                  POSITION GE(NYSE)    USD 12,4            11,7           LONG TERM MARKET RECOVERY MI(NYSE)     USD 5,1             4,4              LONG TERM STOCK DISTRESSED GCI(NYSE)   USD 4,5               5,05         LONG TERM RESULTS  FINL(NASDAQ) USD 8            8                LONG TERM    STRONG CONSENSUS HITK(NASDAQ) USD 12             14      LONG TERM    STRONG RESULTS  RT(NYSE)           USD 7,93       7,95            LONG TERM   STRONG RESULTS CHRS(NASDAQ) USD 3,67         4,5           LONG TERM THESTREET.COM RECOMEND.

Continua la lettura con la fonte di questo articolo:
long term stock list trading-news update 7/20/09

In red positive intraday performance, we signal: – we are selling OREX (NASDAQ) at 6,45 with 20% gain  – IDIX (NASDAQ) bought today at open already up 8% – CYTR (NASDAQ) up 8% – TRGT (NASDAQ) surpassing 8 usd, up 6% to 8,35 usd – INCY (NASDAQ) up 4,5% to 4 usd – GTXI (NASDAQ) up 5,5% – NGSX (NASDAQ) up 5% above 7 usd – OCLS (NASDAQ) up 7,5% – We have added  IDIX (NASDAQ) with strong consensus  and SNTS(nasdaq) with a FDA decison for its product by december, both for LT – DDSS (NASDAQ): Labopharm receives complete response letter from the U.S. FDA for novel antidepressant, no safety or efficay issues, manifacturig issues, we are still hold ing the stock in spite of possible today sell off   TICKER                       BUY AREA          QUOTE NOW     POSITION            DRIVER IDIX (NASDAQ)        USD  4,44              4,8      LONG TERM      STRONG CONSENSUS       SNTS (NASDAQ)     USD   2,81              3      LONG TERM    FDA REVIEW Zegerid BY DECEMBER BFRM (NASDAQ)        USD   2,85           2            LONG TERM OVERSOLD CONDITIONS OCLS (NASDAQ) USD 2,85     2,75          LONG TERM    MORE UPSIDE TRGT (NASDAQ) USD 5,5          8,33  STRONG BUY     Targacept’s TC-5214 results OREX (NASDAQ) USD 5,35     6,45 SOLD(+20%)   FOLD (NASADQ) USD 10           10,4  LONG TERM     PLICERA, AMIGAL STRONG CONSENSUS SOMX (NASDAQ) USD 1,10       1,38   SOLD (+25%)     DDSS (NASDAQ)  USD 2,65       1,9     SHORT TERM   TRAZODONE FDA PDUFA 7/18/09 XNPT (NASDAQ)  USD 21,85      20,3    LONG TERM    XP19986  POSITIVE TRIAL 6/30/09 VNDA (NASDAQ) 12,1                 12,9        REBUYING      FANAT APPROVED 5/6/09 CYTR (NASDAQ)   USD 1,02      1,2        LONG TERM    STRONG CONSENSUS  JAZZ (NASDAQ)    USD 4,95     4       LONG TERM         STRONG CONSENSUS PARD (NASDAQ)    USD 5          5,9     PROFIT TAKING(+18%)       PARD (NASDAQ) USD 6,6 rebought 7/2    7,1  LONG TERM       STRONG CONSENSUS INCY (NASDAQ) USD 3,5         4    LONG TERM            STRONG CONSENSUS   ISTA (NASDAQ) USD 4,1         4,45       LONG TERM          BEPREVE FDA PDUFA  9/12/09 JAV (AMEX)      USD 1,3          1,55       LONG TERM         STRONG CONSENSUS  SLXP (NASDAQ) USD 9,9        11,15  LONG TERM  STRONG CONSENSUS FDA PDUFA 9/9/09 MAPP (NASDAQ) USD 11,3       10  REBUYING LONG TERM STRONG CONSENSUS   ARYX (NASDAQ) USD            4,5       SOLD 2,5 (-45%) ARRY (NASDAQ) USD 3,1      3,2    LONG TERM          CLINICAL TRIAL 7/8/09 GTXI (NASDAQ)   USD 9,5      8,7     LONG TERM         FDA PDUFA 10/30/09 UTHR (NASDAQ) USD 84         85  LONG TERM        FDA PDUFA 7/30/09 NGSX (NASDAQ) USD 6,4      7,3  LONG TERM        FDA PDUFA 8/16/09 VICL (NASDAQ)  USD 3             2,7    LONG TERM      SWINE FLU STAA (NASDAQ)  USD 3,3        2,3 LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH (NASDAQ)  7,9               7,6  LONG TERM          FDA PDUFA 9/24/09 AMAG (NASDAQ) 52,8        50,8  LONG TERM        FDA APPROVES FERAHEME 6/30/09 XOMA (NASDAQ) 1,2    0,78  LONG TERM  OVERSOLD HEB (AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB (AMEX) was rebought after 100% gain (see old posts) MRNA (NASDAQ)  3,3            1,5      LONG TERM      OVERSOLD RIGL (NASDAQ) USD 10           14,4     LONG TERM     STRONG CONSENSUS MITI (NASDAQ) USD 6              5       LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3         7,95    SOLD(-4%)      SVNT (NASDAQ) USD 7,10        13       SOLD(+90%) NPSP (NASDAQ) 3,1 USD        4,75     SOLD(+50%) SCLN (NASDAQ) 2,25 USD        2,7     SOLD (+20%)  LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD  (posts from 5/26)  PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)  PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD         9,5  LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,39 SOLD (-35%) ANPI (NASDAQ) 2 USD           1,39 SOLD(-30%) MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)  LTERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD      11,4   LONG TERM   STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD     2,35       LONG TERM  CLINICAL DATA  3 Q

Guarda Originale:
trading-news biopharma stock list update 7/20/09

In red positive intraday performance, we signal: – we sold OREX (NASDAQ) at 6,45 with 20% gain  – TRGT (NASDAQ) surpassing 8 usd, up 6% to 8,4 usd – CYTR (NASDAQ) up 8%  – INCY (NASDAQ) up 4,5% to 4 usd – GTXI (NASDAQ) up 5,5% – NGSX (NASDAQ) up 5% well above 7 usd – OCLS (NASDAQ) up 7,5% – We have added  IDIX (NASDAQ) with strong consensus  and SNTS(nasdaq) with a FDA decison for its product by december, both for LT – DDSS (NASDAQ): Labopharm receives complete response letter from the U.S. FDA for novel antidepressant, no safety or efficay issues, manifacturig issues, we are still hold ing the stock in spite of possible today sell off   TICKER                       BUY AREA          QUOTE NOW     POSITION            DRIVER IDIX (NASDAQ)        USD  4,44              5    LONG TERM      STRONG CONSENSUS       SNTS (NASDAQ)     USD   2,81              3      LONG TERM    FDA REVIEW Zegerid BY DECEMBER BFRM (NASDAQ)        USD   2,85           2            LONG TERM OVERSOLD CONDITIONS OCLS (NASDAQ) USD 2,85     2,75          LONG TERM    MORE UPSIDE TRGT (NASDAQ) USD 5,5          8,4  STRONG BUY     Targacept’s TC-5214 results OREX (NASDAQ) USD 5,35     6,45 SOLD(+20%)   FOLD (NASADQ) USD 10           10,4  LONG TERM     PLICERA, AMIGAL STRONG CONSENSUS SOMX (NASDAQ) USD 1,10       1,38   SOLD (+25%)     DDSS (NASDAQ)  USD 2,65      2     SHORT TERM   TRAZODONE FDA PDUFA 7/18/09 XNPT (NASDAQ)  USD 21,85      20,5    LONG TERM    XP19986  POSITIVE TRIAL 6/30/09 VNDA (NASDAQ) 12,1                 12,95        REBUYING      FANAT APPROVED 5/6/09 CYTR (NASDAQ)   USD 1,02      1,2        LONG TERM    STRONG CONSENSUS  JAZZ (NASDAQ)    USD 4,95     4       LONG TERM         STRONG CONSENSUS PARD (NASDAQ)    USD 5          5,9     PROFIT TAKING(+18%)       PARD (NASDAQ) USD 6,6 rebought 7/2    7,1  LONG TERM       STRONG CONSENSUS INCY (NASDAQ) USD 3,5         4    LONG TERM            STRONG CONSENSUS   ISTA (NASDAQ) USD 4,1         4,45       LONG TERM          BEPREVE FDA PDUFA  9/12/09 JAV (AMEX)      USD 1,3          1,6       LONG TERM         STRONG CONSENSUS  SLXP (NASDAQ) USD 9,9        11,15  LONG TERM  STRONG CONSENSUS FDA PDUFA 9/9/09 MAPP (NASDAQ) USD 11,3       10  REBUYING LONG TERM STRONG CONSENSUS   ARYX (NASDAQ) USD            4,5       SOLD 2,5 (-45%) ARRY (NASDAQ) USD 3,1      3,2    LONG TERM          CLINICAL TRIAL 7/8/09 GTXI (NASDAQ)   USD 9,5      8,7     LONG TERM         FDA PDUFA 10/30/09 UTHR (NASDAQ) USD 84         85  LONG TERM        FDA PDUFA 7/30/09 NGSX (NASDAQ) USD 6,4      7,4  LONG TERM        FDA PDUFA 8/16/09 VICL (NASDAQ)  USD 3             2,7    LONG TERM      SWINE FLU STAA (NASDAQ)  USD 3,3        2,3 LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH (NASDAQ)  7,9               7,6  LONG TERM          FDA PDUFA 9/24/09 AMAG (NASDAQ) 52,8        50,8  LONG TERM        FDA APPROVES FERAHEME 6/30/09 XOMA (NASDAQ) 1,2    0,78  LONG TERM  OVERSOLD HEB (AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB (AMEX) was rebought after 100% gain (see old posts) MRNA (NASDAQ)  3,3            1,5      LONG TERM      OVERSOLD RIGL (NASDAQ) USD 10           14,4     LONG TERM     STRONG CONSENSUS MITI (NASDAQ) USD 6              5       LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3         7,95    SOLD(-4%)      SVNT (NASDAQ) USD 7,10        13       SOLD(+90%) NPSP (NASDAQ) 3,1 USD        4,75     SOLD(+50%) SCLN (NASDAQ) 2,25 USD        2,7     SOLD (+20%)  LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD  (posts from 5/26)  PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)  PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD         9,5  LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,39 SOLD (-35%) ANPI (NASDAQ) 2 USD           1,39 SOLD(-30%) MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)  LTERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD      11,4   LONG TERM   STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD     2,35       LONG TERM  CLINICAL DATA  3 Q

Per approfondire consulta articolo originale:
trading-news biopharma stock list update: orex, trgt

OREX (NASDAQ)  up more then 50% approching 9 usd in AH following this news: -  UPDATE – Orexigen to unveil obesity trial results on Monday   In red strong friday performances: TRGT(NASDAQ) up another 10% at 8 USD JAV(AMEX) up 10% above 1,5 usd with the strong consensus We also signal strong intraday performances from VNDA (NASDAQ) at 13 usd, ALTH (NASDAQ) above 8 usd,  ACAD (NASDAQ) at 2,3 usd, AMAG (NASDAQ) above 50 usd, SPPI (NASDAQ) up 7%, OREX (NASDAQ) up 5%, STAA(NASDAQ) up 4% We added BFRM(NASDAQ) for the long term TICKER                           BUY AREA          QUOTE NOW     POSITION           DRIVER BFRM (NASDAQ) 2,85           2,1             LONG TERM OVERSOLD CONDITIONS OCLS (NASDAQ) USD 2,85     2,6           LONG TERM    MORE UPSIDE TRGT (NASDAQ) USD 5,5          8    STRONG BUY     Targacept’s TC-5214 results OREX (NASDAQ) USD 5,35        8,9  AH   LONG TERM      CONTRAVE STRONG CONSENSUS FOLD (NASADQ) USD 10           10,4   LONG TERM     PLICERA, AMIGAL STRONG CONSENSUS SOMX (NASDAQ) USD 1,10       1,38   SOLD (+25%)     DDSS (NASDAQ)  USD 2,65       2,2     SHORT TERM   TRAZODONE FDA PDUFA 7/18/09 XNPT (NASDAQ)  USD 21,85      20,4    LONG TERM    XP19986  POSITIVE TRIAL 6/30/09 VNDA (NASDAQ) 12,1                 13,2        REBUYING      FANAT APPROVED 5/6/09 CYTR (NASDAQ)   USD 1,02      1,1        LONG TERM    STRONG CONSENSUS  JAZZ (NASDAQ)    USD 4,95     3,9     LONG TERM         STRONG CONSENSUS PARD (NASDAQ)    USD 5          5,9     PROFIT TAKING(+18%)       PARD (NASDAQ) USD 6,6 rebought 7/2    7,25  LONG TERM       STRONG CONSENSUS INCY (NASDAQ) USD 3,5         3,9        LONG TERM            STRONG CONSENSUS   ISTA (NASDAQ) USD 4,1         4,45       LONG TERM          BEPREVE FDA PDUFA  9/12/09 JAV (AMEX)      USD 1,3          1,55       LONG TERM         STRONG CONSENSUS  SLXP (NASDAQ) USD 9,9        11,2  LONG TERM  STRONG CONSENSUS FDA PDUFA 9/9/09 MAPP (NASDAQ) USD 11,3       10,2  REBUYING LONG TERM STRONG CONSENSUS   ARYX (NASDAQ) USD            4,5       SOLD 2,5 (-45%) ARRY (NASDAQ) USD 3,1      3,2    LONG TERM          CLINICAL TRIAL 7/8/09 GTXI (NASDAQ)   USD 9,5      8,2     LONG TERM         FDA PDUFA 10/30/09 UTHR (NASDAQ) USD 84         83,5  LONG TERM        FDA PDUFA 7/30/09 NGSX (NASDAQ) USD 6,4         6,95   LONG TERM        FDA PDUFA 8/16/09 VICL (NASDAQ)  USD 3             2,6    LONG TERM      SWINE FLU STAA (NASDAQ)  USD 3,3        2,3   LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH (NASDAQ)  7,9               8,2   LONG TERM          FDA PDUFA 9/24/09 AMAG (NASDAQ) 52,8        50,2  LONG TERM        FDA APPROVES FERAHEME 6/30/09 XOMA (NASDAQ) 1,2    0,75  LONG TERM  OVERSOLD HEB (AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB (AMEX) was rebought after 100% gain (see old posts) MRNA (NASDAQ)  3,3            1,5      LONG TERM      OVERSOLD RIGL (NASDAQ) USD 10           14     LONG TERM     STRONG CONSENSUS MITI (NASDAQ) USD 6              5       LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3         7,95    SOLD(-4%)      SVNT (NASDAQ) USD 7,10        13       SOLD(+90%) NPSP (NASDAQ) 3,1 USD        4,75     SOLD(+50%) SCLN (NASDAQ) 2,25 USD        2,7     SOLD (+20%)  LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD  (posts from 5/26)  PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)  PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD         9,7  LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,39 SOLD (-35%) ANPI (NASDAQ) 2 USD           1,39 SOLD(-30%) MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)  LTERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD      11,2   LONG TERM   STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD     2,3       LONG TERM  CLINICAL DATA  3 Q.

Fonte Articolo:
trading-news biopharma stock list update: orex, trgt, jav

  YHOO(NASDAQ) up 4% in regular trading, up another 2% above 17 in AH usd on this news: Yahoo board member Icahn wants Microsoft deal   We are selling ELY(NYSE) with 7% gain on lowered guidance In red positive friday performances: we signal SAY(NYSE) up 10% and HITK(NASDAQ) up 8% We are adding MI(NYSE) for the long term due the distressed conditions and recent upgrades We are adding GE(NYSE) a classic long term play for market recovery     TICKER            BUY AREA          QUOTE NOW                  POSITION GE(NYSE)    USD 12,4            11,7           LONG TERM MARKET RECOVERY MI(NYSE)     USD 5,1             4,6              LONG TERM STOCK DISTRESSED GCI(NYSE)   USD 4,5                4,8            LONG TERM RESULTS  FINL(NASDAQ) USD 8            8,1                 LONG TERM    STRONG CONSENSUS HITK(NASDAQ) USD 12             13,5      LONG TERM    STRONG RESULTS  RT(NYSE)           USD 7,93       7,4            LONG TERM   STRONG RESULTS CHRS(NASDAQ) USD 3,67         4,4           LONG TERM THESTREET.COM RECOMEND.

Per approfondire consulta articolo originale:
trading-news long term stock list: yhoo, say, hitk

XOMA Announces Positive Results From U.S. Phase 1 Trial of XOMA 052 in Type 2 Diabetes :   In red  positive intraday performances – We sold SOMX (NASDAQ) with 25% gain – XOMA(NASDAQ) up 8% before data release – NGSX(NASDAQ) up 8% TICKER              BUY AREA          QUOTE NOW     POSITION              DRIVER OREX(NASDAQ) USD 5,35             5,4      LONG TERM              CONTRAVE STRONG CONSENSUS FOLD(NASADQ) USD 10             10,4   LONG TERM     PLICERA, AMIGAL STRONG CONSENSUS SOMX(NASDAQ) USD 1,10              1,38 SOLD(+25%)     DDSS (NASDAQ)  USD 2,65             2,3      SHORT TERM        TRAZODONE FDA PDUFA 7/18/09 XNPT (NASDAQ)  USD 21,85          19,3       LONG TERM      XP19986  POSITIVE TRIAL 6/30/09 VNDA (NASDAQ) 12,1                     11,5         REBUYING         FANAT APPROVED 5/6/09 CYTR (NASDAQ)   USD 1,02      1,15        LONG TERM    STRONG CONSENSUS  JAZZ (NASDAQ)    USD 4,95        4,1      LONG TERM            STRONG CONSENSUS PARD (NASDAQ)    USD 5               5,9 PROFIT TAKING(+18%)       PARD (NASDAQ) USD 6,6 rebought 7/2     6,85   LONG TERM       STRONG CONSENSUS INCY (NASDAQ) USD 3,5                  3,55         LONG TERM            STRONG CONSENSUS   ISTA (NASDAQ) USD 4,1                 4,3        LONG TERM          BEPREVE FDA PDUFA  9/12/09 JAV (AMEX)      USD 1,3                 1,3        LONG TERM         STRONG CONSENSUS  SLXP (NASDAQ) USD 9,9          10,9    LONG TERM      STRONG CONSENSUS FDA PDUFA 9/9/09 MAPP (NASDAQ) USD 11,3         10,5  REBUYING LONG TERM STRONG CONSENSUS   ARYX (NASDAQ) USD 4,5                                  SOLD 2,5 (-45%) ARRY (NASDAQ) USD 3,1           3        LONG TERM          CLINICAL TRIAL 7/8/09 GTXI (NASDAQ)   USD 9,5          8,2    LONG TERM         FDA PDUFA 10/30/09 UTHR (NASDAQ) USD 84             84    LONG TERM        FDA PDUFA 7/30/09 NGSX (NASDAQ) USD 6,4             6,5   LONG TERM        FDA PDUFA 8/16/09 VICL (NASDAQ)  USD 3                 2,6  LONG TERM      SWINE FLU STAA (NASDAQ)  USD 3,3            2,15  LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH (NASDAQ)  7,9                 7,7  LONG TERM          FDA PDUFA 9/24/09 AMAG (NASDAQ) 52,8        46,1  LONG TERM        FDA APPROVES FERAHEME 6/30/09 XOMA (NASDAQ) 1,2    0,9  LONG TERM  conference call to review clinical results on july 14 p.m HEB (AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB (AMEX) was rebought after 100% gain(see old posts) MRNA (NASDAQ)  3,3                   1,4          LONG TERM      OVERSOLD RIGL (NASDAQ) USD 10           14       LONG TERM     STRONG CONSENSUS MITI (NASDAQ) USD 6              4,9   LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3           7,95 SOLD(-4%)      SVNT (NASDAQ) USD 7,10            13 SOLD(+90%) NPSP (NASDAQ) 3,1 USD            4,75 SOLD(+50%) SCLN (NASDAQ) 2,25 USD            2,7 SOLD(+20%)    LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD           9,5    LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,39 SOLD (-35%) ANPI (NASDAQ) 2 USD           1,39 SOLD(-30%) MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)  LTERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD        11,6   LONG TERM   STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD         2,1       LONG TERM  CLINICAL DATA  3 Q

Per approfondire consulta la fonte:
trading-news biopharma stock list update:xoma

Top gainers: – SOMX(NASDAQ) up 25%  – CYTR(NASDAQ) up 12%  – MAPP(NASDAQ) up 7% – SLXP(NASDAQ) up 6% – RIGL(NASDAQ) surpassing 14 USD   In red other positive performances   TICKER              BUY AREA          QUOTE NOW     POSITION              DRIVER OREX(NASDAQ) USD 5,35             5,35      LONG TERM              CONTRAVE STRONG CONSENSUS FOLD(NASADQ) USD 10             10    LONG TERM     PLICERA, AMIGAL STRONG CONSENSUS SOMX(NASDAQ) USD 1,10              1,3     LONG TERM              SILENOR DDSS (NASDAQ)  USD 2,65             2,4      SHORT TERM        TRAZODONE FDA PDUFA 7/18/09 XNPT (NASDAQ)  USD 21,85          19,3     LONG TERM      XP19986  POSITIVE TRIAL 6/30/09 VNDA (NASDAQ) 12,1                     11,1         REBUYING         FANAT APPROVED 5/6/09 CYTR (NASDAQ)   USD 1,02      1,1        LONG TERM    STRONG CONSENSUS  JAZZ (NASDAQ)    USD 4,95        4,2      LONG TERM            STRONG CONSENSUS PARD (NASDAQ)    USD 5               5,9 PROFIT TAKING(+18%)       PARD (NASDAQ) USD 6,6 rebought 7/2     6,75    LONG TERM       STRONG CONSENSUS INCY (NASDAQ) USD 3,5                  3,65         LONG TERM            STRONG CONSENSUS   ISTA (NASDAQ) USD 4,1                 4,3        LONG TERM          BEPREVE FDA PDUFA  9/12/09 JAV (AMEX)      USD 1,3                 1,3        LONG TERM         STRONG CONSENSUS  SLXP (NASDAQ) USD 9,9          10,7    LONG TERM      STRONG CONSENSUS FDA PDUFA 9/9/09 MAPP (NASDAQ) USD 11,3         11  REBUYING LONG TERM STRONG CONSENSUS   ARYX (NASDAQ) USD 4,5                                  SOLD 2,5 (-45%) ARRY (NASDAQ) USD 3,1           3,1        LONG TERM          CLINICAL TRIAL 7/8/09 GTXI (NASDAQ)   USD 9,5          8    LONG TERM         FDA PDUFA 10/30/09 UTHR (NASDAQ) USD 84             81,1    LONG TERM        FDA PDUFA 7/30/09 NGSX (NASDAQ) USD 6,4             6    LONG TERM        FDA PDUFA 8/16/09 VICL (NASDAQ)  USD 3                 2,55  LONG TERM      SWINE FLU STAA (NASDAQ)  USD 3,3            2,1  LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH (NASDAQ)  7,9           7,6    LONG TERM          FDA PDUFA 9/24/09 AMAG (NASDAQ) 52,8        47  LONG TERM        FDA APPROVES FERAHEME 6/30/09 XOMA (NASDAQ) 1,2    0,82  LONG TERM  conference call to review clinical results on july 14 p.m HEB (AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB (AMEX) was rebought after 100% gain (see old posts) MRNA (NASDAQ)  3,3                   1,4          LONG TERM      OVERSOLD RIGL (NASDAQ) USD 10           14       LONG TERM     STRONG CONSENSUS MITI (NASDAQ) USD 6               4,95      LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3              8,1         LONG TERM    AFRESA CLINICAL TRIAL 6/8/09 SVNT (NASDAQ) USD 7,10            13 SOLD(+90%) NPSP (NASDAQ) 3,1 USD            4,75 SOLD(+50%) SCLN (NASDAQ) 2,25 USD            2,7 SOLD(+20%)    LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD           9,7      LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,39 SOLD (-35%) ANPI (NASDAQ) 2 USD           1,39 SOLD(-30%) MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)  LTERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD        11,4    LONG TERM   STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,1       LONG TERM  CLINICAL DATA  3 Q.

Vai a vedere articolo:
trading-news biopharma stock list update: top gainers

In red positive performances, we signal several outperforming retailers with more way to run: LZB(NYSE) up 8,5% CTRN(NASDAQ) up 4,5% PIR(NYSE) up 4,5% MOV(NYSE) up 4% CHRS(NASDAQ) up 4% ZUMZ(NASDAQ) up 4% Other strong performances: VRGY(NASDAQ) +5% RT(NYSE) +4%   TICKER            BUY AREA          QUOTE NOW                  POSITION RT(NYSE)           USD 7,93       7,4              LONG TERM   STRONG RESULTS CHRS(NASDAQ) USD 3,67          3,8              LONG TERM THESTREET.COM RECOMEND. ELY(NYSE)        USD 4,9                5,2                LONG TERM LAZARD UPGRADE ESLR(NASDAQ)   USD 2,25                2             SHORT TERM   JPM UPGRADE ZZ(NYSE)            USD 2                      1,7              STOCK DISTRESSED APOL(NASDAQ)  USD 69,4               65,4      LONG TERM MORE UPSIDE RIMM(NASDAQ) USD 77,9             66,5           LONG TERM STRONG CONSENSUS FLOW(NASDAQ)   USD 2,35          2        LONG TERM STOCK DISTRESSED  ETFC(NASDAQ)  USD 1,27                 1,2                LONG TERM BOTTOMING SJM(NYSE)  USD      43,6                48,6           LONG TERM  AGN(NYSE) USD  45,3              45,9     LONG TERM  PIR(NYSE)  USD 2,2               1,9  LONG TERM LZB(NYSE)  USD  4,6               5,25    LONG TERM FDS(NYSE) USD 52,3             50,3  LONG TERM STRONG RESULTS ZUMZ(NASDAQ) USD 8,6       8,2      LONG TERM OVERSOLD YHOO(NASDAQ) USD 16,6           15    LONG TERM STRONG CONSENSUS CTRN(NASDAQ)  22,8           25,6  LONG TERM UNDERVALUED SHFL(NASDAQ) 5,5            6,35    HOLD LONG TERM NCS(NYSE)      4,05           2,35   HOLD LONG TERM OVERSOLD SAY(NYSE)       3,65            3,7    HOLD LONG TERM MOV(NYSE)         9,5       9,9   HOLD LONG TERM UNDERVALUED JTX(NYSE)            4,9        7,4 PROFIT TAKED(+50%)            CMTL(NASDAQ) 28,8               31,5  HOLD  LONG TERM  GIII(NASDAQ)   9,8          10 HOLD LONG TERM UNDERVALUED AINV(NASDAQ)    5,4                  6,4 PROFIT TAKING(+20%)      COT(NYSE)           2,8        PROFIT TAKED(+170%) 5/2(see old posts) TLB(NYSE)            4,6       6/10 PROFIT TAKED 5 (+10%) CPSL(NSDAQ)      3,05                 2,3            HOLD BBI(NYSE)           1,04                  0,6       HOLD OVERSOLD THC(NYSE)           2,6           2,95     HOLD SKS(NYSE)           3,45         4,65 PROFIT TAKING(+35%)       SHLD(NASDAQ)      60,6                 6/11  PROFIT TAKED 69,8 (+17%)           VRGY(NASDAQ)    12,6       11,3   HOLD SAFM(NASDAQ)      47     45,7  HOLD PERY(NASDAQ)       8,9      6,8   HOLD LONG TERM UNDERVALUED

Fonte:
long-term-stock-list-trading-news-update:retailers strong performances

CytRx’s INNO-206 Demonstrates Statistically Significant Tumor Shrinkage in Animal Trial for Breast Cancer : – CYTR(NASDAQ) up 12% – SOMX(NASDAQ) up 20%  – RIGL(NASDAQ) surpassing 14 USD – MAPP(NASDAQ) up 7% – SLXP(NASDAQ) up 6% In red other positive performances     In red other positive performances TICKER              BUY AREA          QUOTE NOW     POSITION              DRIVER OREX(NASDAQ) USD 5,35             5,3      LONG TERM              CONTRAVE STRONG CONSENSUS FOLD(NASADQ) USD 10             10    LONG TERM     PLICERA, AMIGAL STRONG CONSENSUS SOMX(NASDAQ) USD 1,10              1,2      LONG TERM              SILENOR DDSS (NASDAQ)  USD 2,65             2,4      SHORT TERM        TRAZODONE FDA PDUFA 7/18/09 XNPT (NASDAQ)  USD 21,85          19,4     LONG TERM      XP19986  POSITIVE TRIAL 6/30/09 VNDA (NASDAQ) 12,1                     11,1         REBUYING         FANAT APPROVED 5/6/09 CYTR (NASDAQ)   USD 1,02      1,1        LONG TERM    STRONG CONSENSUS  JAZZ (NASDAQ)    USD 4,95        4,2      LONG TERM            STRONG CONSENSUS PARD (NASDAQ)    USD 5               5,9 PROFIT TAKING(+18%)       PARD (NASDAQ) USD 6,6 rebought 7/2     6,75    LONG TERM       STRONG CONSENSUS INCY (NASDAQ) USD 3,5                  3,65         LONG TERM            STRONG CONSENSUS   ISTA (NASDAQ) USD 4,1                 4,3        LONG TERM          BEPREVE FDA PDUFA  9/12/09 JAV (AMEX)      USD 1,3                 1,3        LONG TERM         STRONG CONSENSUS  SLXP (NASDAQ) USD 9,9          10,7    LONG TERM      STRONG CONSENSUS FDA PDUFA 9/9/09 MAPP (NASDAQ) USD 11,3         11  REBUYING LONG TERM STRONG CONSENSUS   ARYX (NASDAQ) USD 4,5                                  SOLD 2,5 (-45%) ARRY (NASDAQ) USD 3,1           3,1        LONG TERM          CLINICAL TRIAL 7/8/09 GTXI (NASDAQ)   USD 9,5          8    LONG TERM         FDA PDUFA 10/30/09 UTHR (NASDAQ) USD 84             81,1    LONG TERM        FDA PDUFA 7/30/09 NGSX (NASDAQ) USD 6,4             6    LONG TERM        FDA PDUFA 8/16/09 VICL (NASDAQ)  USD 3                 2,55  LONG TERM      SWINE FLU STAA (NASDAQ)  USD 3,3            2,1  LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH (NASDAQ)  7,9           7,6    LONG TERM          FDA PDUFA 9/24/09 AMAG (NASDAQ) 52,8        47  LONG TERM        FDA APPROVES FERAHEME 6/30/09 XOMA (NASDAQ) 1,2    0,82  LONG TERM  conference call to review clinical results on july 14 p.m HEB (AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB (AMEX) was rebought after 100% gain (see old posts) MRNA (NASDAQ)  3,3                   1,4          LONG TERM      OVERSOLD RIGL (NASDAQ) USD 10           14       LONG TERM     STRONG CONSENSUS MITI (NASDAQ) USD 6               4,95      LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3              8,1         LONG TERM    AFRESA CLINICAL TRIAL 6/8/09 SVNT (NASDAQ) USD 7,10            13 SOLD(+90%) NPSP (NASDAQ) 3,1 USD            4,75 SOLD(+50%) SCLN (NASDAQ) 2,25 USD            2,7 SOLD(+20%)    LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD           9,7      LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,39 SOLD (-35%) ANPI (NASDAQ) 2 USD           1,39 SOLD(-30%) MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)  LTERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD        11,4    LONG TERM   STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,1       LONG TERM  CLINICAL DATA  3 Q.

Continua la lettura con la fonte di questo articolo:
trading-news biopharma stock list update: cytr, rigl, mapp, slxp

long term trading-news stock list update: – We are adding APOL(NASDAQ) with strong quarterly results, more upside and upgrading coming  – In red strong intraday performances from CMTL(NASAQ) and VRGY(NASDAQ)   TICKER            BUY AREA         QUOTE NOW           POSITION APOL(NASDAQ)  ISD 69,4                71,5                 LONG TERM MORE UPSIDE RIMM(NASDAQ) USD 77,9                71,1               LONG TERM STRONG CONSENSUS FLOW(NASDAQ)   USD 2,35            2,35                  LONG TERM STOCK DISTRESSED  ETFC(NASDAQ)  USD 1,27                 1,3                 LONG TERM BOTTOMING SJM(NYSE)  USD      43,6                48,7               LONG TERM  AGN(NYSE) USD  45,3                 47,7           LONG TERM  PIR(NYSE)  USD 2,2                    2             LONG TERM LZB(NYSE)  USD  4,6                        4,75         LONG TERM FDS(NYSE) USD 52,3                49,9   LONG TERM STRONG RESULTS ZUMZ(NASDAQ) USD 8,6               8,1       LONG TERM BOTTOMING YHOO(NASDAQ) USD 16,6           15,7      LONG TERM STRONG CONSENSUS CTRN(NASDAQ)  22,8             25,9  HOLD LONG TERM  SHFL(NASDAQ) 5,5            6,6     HOLD LONG TERM NCS(NYSE)      4,05           2,7     HOLD LONG TERM OVERSOLD SAY(NYSE)       3,65            3,1  HOLD LONG TERM MOV(NYSE)         9,5             10,6   HOLD LONG TERM JTX(NYSE)            4,9        7,4 PROFIT TAKED(+50%)            CMTL(NASDAQ) 28,8               31,9   HOLD LONG TERM  GIII(NASDAQ)   9,8                 11,5  HOLD LONG TERM AINV(NASDAQ)    5,4                  6,4 PROFIT TAKING(+20%)      COT(NYSE)           2,8        PROFIT TAKED(+170%) 5/2(see old posts) TLB(NYSE)            4,6       6/10 PROFIT TAKED 5 (+10%) CPSL(NSDAQ)      3,05                 2,5              HOLD BBI(NYSE)           1,04                  0,7          HOLD THC(NYSE)           2,6               2,85        HOLD SKS(NYSE)           3,45         4,45       HOLD SHLD(NASDAQ)      60,6                 6/11  PROFIT TAKED 69,8 (+17%)           VRGY(NASDAQ)    12,6           12,2  HOLD SAFM(NASDAQ)      47         45   HOLD PERY(NASDAQ)       8,9       7, 3  HOLD LONG TERM UNDERVALUED

Il seguito di questo articolo:
trading news long term stock list update. apol, cmtl, vrgy

– AMAG PHARMACEUTICALS: FDA Approves Feraheme to Treat Iron Deficiency Anemia in Adult Chronic Kidney Disease Patients – In red other strong yesterday performances   – we are adding XNPT(NASDAQ) for the long term due its strong data from clinical trial   TICKER              BUY AREA          QUOTE NOW     POSITION              DRIVER XNPT(NASDAQ)  USD 21,85           23,2            LONG TERM    CLINICAL DATA VNDA(NASDAQ) 12,1                     11,8            REBUYING         FANAT APPROVED CYTR(NASDAQ)   USD 1,02              1,1               LONG TERM    STRONG CONSENSUS  JAZZ(NASDAQ)    USD 4,95             3,7            LONG TERM            CLINICAL DATA  PARD(NASDAQ)    USD 5                 5,9 PROFIT TAKING(+18%)       INCY(NASDAQ) USD 3,5                     3,3           LONG TERM            CLINICAL DATA   ISTA(NASDAQ) USD 4,1                       4,2        LONG TERM               BEPREVE FDA APPROVAL  JAV(AMEX)      USD 1,3                    1,25          LONG TERM         STRONG CONSENSUS  SLXP(NASDAQ) USD 9,9                    9,9       LONG TERM         STRONG CONSENSUS MAPP(NASDAQ) USD 11,3            12,3       REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,2           LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,2            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           9,3       LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84             83,4           LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4               5,7 LONG TERM        FDA ANNONCEMENT VICL(NASDAQ)  USD 3                 2,7       LONG TERM      SWINE FLU STAA(NASDAQ)  USD 3,3                 2,41 LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                      8,3    LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                 57,5  AH      LONG TERM        FDA APPROVES FERAHEME XOMA(NASDAQ) 1,2                     0,82    LONG TERM         NEXT DATA RELEASE HEB(AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB(AMEX) was rebought after 100% gain (see old posts) MRNA(NASDAQ)  3,3                            1,4          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                       12,2   LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             5              LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,3                  LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                    14      SHORT TERM KRYSTEXXA APPROVAL NPSP (NASDAQ) 3,1 USD                      4,7               LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                     2,6         LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD           11           LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,7     LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,7    LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)    LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                     12,1     LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,2               LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6)  28,2         LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)   25                LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)    6/12 PROFIT TAKING (+35%) SPPI(NASDAQ) 5,85 USD                   7,4 PROFIT TAKING(+28%)    

Continua la lettura con la fonte di questo articolo:
Biopharma stock list: AMAG

Biopharma long term stock list, we are rebuying VNDA(NASDAQ) at current level (around 12 usd) thinking it is going higher after FANAT approval.  We are taking profit on PARD(NASDAQ), with a 18% gain We are taking profit on SPPI(NASDAQ) with a 28% gain Strong performances: -VICL(NASDAQ) up 20% h1n1 flu vaccine promising study -CYTR(NASDAQ) added yesterday, up 10% today   TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER VNDA(NASDAQ) 12,1                            12       REBUYING         FANAT APPROVED CYTR(NASDAQ)   USD 1,02              1,05               LONG TERM    STRONG CONSENSUS  JAZZ(NASDAQ)    USD 4,95             3,7            LONG TERM            CLINICAL DATA  PARD(NASDAQ)    USD 5                 5,9 PROFIT TAKING(+18%)       INCY(NASDAQ) USD 3,5                     3,35           LONG TERM            CLINICAL DATA   ISTA(NASDAQ) USD 4,1                       4,35         LONG TERM               BEPREVE FDA APPROVAL  JAV(AMEX)      USD 1,3                    1,25          LONG TERM         STRONG CONSENSUS  SLXP(NASDAQ) USD 9,9                    9,9       LONG TERM         STRONG CONSENSUS MAPP(NASDAQ) USD 11,3              11,7        REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,3           LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,2            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           9,3       LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84             83           LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4         6    LONG TERM        FDA ANNONCEMENT VICL                 USD 3                 2,65       LONG TERM      SWINE FLU STAA               USD 3,3                 2,15 LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                      8,2    LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                  55      LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                     0,8    LONG TERM         NEXT DATA RELEASE HEB(AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB(AMEX) was rebought after 100% gain (see old posts) MRNA(NASDAQ)  3,3                            1,4          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                       12,3   LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             5,1            LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,3                  LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                    14      SHORT TERM KRYSTEXXA APPROVAL NPSP (NASDAQ) 3,1 USD                      4,7               LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                     2,8         LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD           11           LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,7     LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,75    LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)    LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                     11,9        LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2               LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6)  28,4         LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)   25,2                LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)    6/12 PROFIT TAKING (+35%) SPPI(NASDAQ) 5,85 USD                   7,4 PROFIT TAKING(+28%)    

Articolo completo fonte:
biopharma long term stock list update: vicl, pard, sppi, cytr

Biopharma long term stock list, we are adding CYTR(NASDAQ) with strong clinical data and consensus  s trong performances, strong bull trend, trading-news biopharma stocks on the watch:  – DNDN(NASDAQ): approching 25,5 usd, going higher with strong consensus, fair value above 30 usd – SPPI(NASDAQ) rebought at 5,85 usd pending ZEVALIN FDA decision, above 7 usd now – MAPP(NASDAQ) approching 12 usd Other intraday strong performances: STAA(NASDAQ); XOMA(NASDAQ), both up 15% from oversold conditions   TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER CYTR(NASDAQ)   USD 1,02              0,95                LONG TERM    STRONG CONSENSUS  JAZZ(NASDAQ)    USD 4,95             3,8            LONG TERM            CLINICAL DATA  PARD(NASDAQ)    USD 5                    5,55             LONG TERM           CLINICAL DATA INCY(NASDAQ) USD 3,5                     3,4           LONG TERM            CLINICAL DATA   ISTA(NASDAQ) USD 4,1                       4,55          LONG TERM               BEPREVE FDA APPROVAL  JAV(AMEX)      USD 1,3                    1,25          LONG TERM         STRONG CONSENSUS  SLXP(NASDAQ) USD 9,9                    10,1        LONG TERM         STRONG CONSENSUS MAPP(NASDAQ) USD 11,3              11,9          REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,3           LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,3            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           9,4       LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84             83,5          LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4           5,9    LONG TERM        FDA ANNONCEMENT VICL                 USD 3                 2,2          LONG TERM      SWINE FLU STAA               USD 3,3                 2,3 LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                      8,2    LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                  55      LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                     0,8    LONG TERM         NEXT DATA RELEASE HEB(AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB(AMEX) was rebought after 100% gain (see old posts) MRNA(NASDAQ)  3,3                            1,5          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                         12,3     LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             5            LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,5                  LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                    14,5      SHORT TERM KRYSTEXXA APPROVAL NPSP (NASDAQ) 3,1 USD                      4,8               LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                     2,7         LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD           11,3           LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,8     LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,8    LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)    LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                       12        LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2                       LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6)  27,7           LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)   25,5                 LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)    6/12 PROFIT TAKING (+35%) SPPI(NASDAQ) 5,85 USD                    7,1 PRE MKT.   REBOUGHT SHORT TERM    FDA-ZEVALIN

Per approfondire consulta la fonte:
long term biopharma stock list trading news update. dndn, sppi

Biopharma long term stock list strong results update, strong performances:  -We are adding INCY(NASDAQ), PARD(NASDAQ), JAZZ(NASDAQ) due next clinical data -PARD(NASDAQ) already up 10% today Strong performances, strong bull trend, trading-news biopharma stocks on the watch:    – SVNT(NASDAQ): surpassed 14 Usd, quotes now 14,3 usd  more than+100% from trading news buy area(7 usd, see old post) - MNTA(NASDAQ): now quotes 12 usd with the strong consensus – ACOR(NASDAQ): approching 28 usd, going higher – RIGL(NASDAQ) above 12 usd, going higher – SPPI(NASDAQ) rebought pending ZEVALIN FDA decision, now uo 11% to 6,8 usd Other intraday strong performances: NGSX(NASDAQ); MITI(NASDAQ); SCLN(NASDAQ)   TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER JAZZ(NASDAQ)    USD 4,95              3,9               LONG TERM            CLINICAL DATA  PARD(NASDAQ)    USD 5                    5,5             LONG TERM           CLINICAL DATA INCY(NASDAQ) USD 3,5                     3,5           LONG TERM            CLINICAL DATA   ISTA(NASDAQ) USD 4,1                       4,7          LONG TERM               BEPREVE FDA APPROVAL  JAV(AMEX)      USD 1,3                    1,3          LONG TERM         STRONG CONSENSUS  SLXP(NASDAQ) USD 9,9                    10        LONG TERM         STRONG CONSENSUS MAPP(NASDAQ) USD 11,3              11,4          REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,5           LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,4            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           9,2       LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84              82,3          LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4           6    LONG TERM        FDA ANNONCEMENT VICL                 USD 3                 2,4          LONG TERM      SWINE FLU STAA               USD 3,3                 2  LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                      8,2    LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                  54,7    LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                     0,7    LONG TERM         NEXT DATA RELEASE HEB(AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB(AMEX) was rebought after 100% gain (see old posts) MRNA(NASDAQ)  3,3                            1,5          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                         12,3      LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             5               LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,3                  LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                    14,4      SHORT TERM KRYSTEXXA APPROVAL NPSP (NASDAQ) 3,1 USD                      4,9               LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                     2,6         LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD           12           LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,9     LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,75     LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)    LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                       12        LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,1                       LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6)  28           LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)   24                 LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)    6/12 PROFIT TAKING (+35%) SPPI(NASDAQ) 5,85 USD                     6,8  PRE MKT.   REBOUGHT SHORT TERM    FDA-ZEVALIN 

Prosegue Articolo Originale:
trading-news biopharma stock list: svnt, mnta, acor, rigl, sppi

Biopharma long term stock list strong results update, strong performances:  -We are adding ISTA(NASDAQ): Fda Bepreve co product panel review tomorrow and Fda pending approval 9/12 – SVNTNASDAQ); MNTA(NASDAQ) strong intraday performances and bullish trend     TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER ISTA(NASDAQ) USD 4,1                          4,25                  LONG TERM             BEPREVE  JAV(AMEX)      USD 1,3                    1,25          LONG TERM         STRONG CONSENSUS  SLXP(NASDAQ) USD 9,9                    10         LONG TERM         STRONG CONSENSUS MAPP(NASDAQ) USD 11,3              11          REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,4            LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,2            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           9,2       LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84              84,4           LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4           5,6    LONG TERM        FDA ANNONCEMENT VICL                 USD 3                 2,3          LONG TERM      SWINE FLU STAA               USD 3,3                  1,8 LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                      7,9     LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                  52,6    LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                     0,85    LONG TERM         NEXT DATA RELEASE HEB(AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB(AMEX) was rebought after 100% gain (see old posts) MRNA(NASDAQ)  3,3                            1,5          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                         11,9        LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             4,4                 LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,4                  LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                    13,7      SHORT TERM KRYSTEXXA APPROVAL NPSP (NASDAQ) 3,1 USD                      4,7                LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                     2,3         LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD             11,6             LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,5      LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,7     LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)    LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                        10,4             LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,25                       LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6) 27,3           LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)  25                    LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)      5,4  6/12 PROFIT TAKING (+35%) SPPI(NASDAQ) 5,85 USD                     5,95   REBOUGHT SHORT TERM    FDA-ZEVALIN 

Articolo completo fonte:
trading-news biopharma stock list update: ISTA

Biopharma long term stock list strong results update, strong performances:  - Cell Therapeutics(CTIC;NASDAQ) completes pixantrone NDA submission and requests priority review – in red strong intraday performances SVNT(NASDAQ) going higher: up another7% to 13,3 usd SPPI(NASDAQ) rebound 13% to 6 usd from yesterday sell off     TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER JAV(AMEX)      USD 1,3                    1,25          LONG TERM         STRONG CONSENSUS  SLXP(NASDAQ) USD 9,9                    10         LONG TERM         STRONG CONSENSUS MAPP(NASDAQ) USD 11,3              11          REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,3            LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,15            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           9,2       LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84              83,2            LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4           5,7    LONG TERM        FDA ANNONCEMENT VICL                 USD 3                 2,3          LONG TERM      SWINE FLU STAA               USD 3,3                  1,8 LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                      7,6      LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                  52,4    LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                     0,85    LONG TERM         NEXT DATA RELEASE HEB(AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB(AMEX) was rebought after 100% gain (see old posts) MRNA(NASDAQ)  3,3                            1,5          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                         11,5        LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             4,4                 LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,5                  LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                    13,3      SHORT TERM KRYSTEXXA APPROVAL NPSP (NASDAQ) 3,1 USD                      4,6                 LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                     2,3         LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD             11,2             LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD        1,5      LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,7     LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)    LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                         9,8             LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2                        LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6) 26,6             LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)  24,7                    LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)      5,4  6/12 PROFIT TAKING (+35%) SPPI(NASDAQ) 5,85 USD                        5,95   REBOUGHT SHORT TERM    FDA-ZEVALIN 

Prosegue Articolo Originale:
long term biopharma trading-news stock list update

Tagged with Borsa Valori, business, Denaro, Economia e Finanza, emerpas, Euro, forex , Forex trading, forward foreign exchange, guadagnare con i forex , Guadagnare denaro, guadagni facili, investimenti , investimenti forex , …

Vai a vedere articolo:
iForex Trading online:Hai mai provato ad investire sul Forex? Cosa …

Biopharma long term stock list strong results update:  - we are joining today at open JAV(AMEX) and SLXP(NASDAQ) given the strong consensus for both stocks in the long term. We signal strong intraday performances from NGSX(NASDAQ); MITI(NASDAQ); ACOR(NASDAQ)           TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER JAV(AMEX)      USD 1,35                     1,4            LONG TERM         STRONG CONSENSUS  SLXP(NASDAQ) USD 9,9                    9,8          LONG TERM         STRONG CONSENSUS MAPP(NASDAQ) USD 11,3              11,4          REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,3            LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,1            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           9       LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84              82,7              LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4           6,2     LONG TERM        FDA ANNONCEMENT VICL                 USD 3                 2,4          LONG TERM      SWINE FLU STAA               USD 3,3                  1,9  LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                      7,4       LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                  52,2     LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                     0,9    LONG TERM         NEXT DATA RELEASE HEB(AMEX)    3,3(5%OF CAPITAL)  2,25 SOLD(-35%)                                   HEB(AMEX) was rebought after 100% gain (see old posts) MRNA(NASDAQ)  3,3                            1,6          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                         11,3        LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             4,6                 LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,2                    LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                    12,6       SHORT TERM KRYSTEXXA APPROVAL NPSP (NASDAQ) 3,1 USD                      4,5                 LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                     2,1           LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD             11,8             LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD                          1,5        LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,7      LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)    LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                         9,5             LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2                         LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6) 26,2             LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)  23,8                    LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)      5,4  6/12 PROFIT TAKING (+35%) SPPI(NASDAQ) 5,85 USD                        5,6     REBOUGHT SHORT TERM    FDA-ZEVALIN 

Guarda Originale:
trading-news biopharma long term stock list update

Biopharma long term stock list strong results update:  MEDX(NASDAQ) 8,70 PROFIT TAKING   MEDX(NASDAQ): 8,7 PROFIT TAKING(+20%)  DNDN(NASDAQ) upgraded   TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER MAPP(NASDAQ) USD 11,3              11          REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,4            LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,2            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           8,5         LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84              83              LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4           7,5 PRE MKT.      LONG TERM        FDA ANNONCEMENT VICL                 USD 3                 2,5          LONG TERM      SWINE FLU STAA               USD 3,3                   2  LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                      7,65       LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                    53,9    LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                     0,95    LONG TERM         NEXT DATA RELEASE HEB(AMEX)    3,3(5%OF CAPITAL)  2,55         SHORT TERM     AMPLIGEN                                HEB (AMEX) was rebought after 100% gain (see old posts) MRNA(NASDAQ)  3,3                            1,6          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                         11,6        LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             4,6                 LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,6                    LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                    12,1       SHORT TERM KRYSTEXXA APPROVAL NPSP (NASDAQ) 3,1 USD                      4,7                LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                     2,1           LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD             12,3             LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD                          1,55        LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,9      LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD   8,7 PROFIT TAKING(+20%)    LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                         9,9             LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,3                         LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6) 26,1                LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)  26,1                        LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)      5,4  6/12 PROFIT TAKING (+35%)

Fonte Articolo:
trading-news biopharma long term stock list update strong results: NGSX(NASDAQ), MEDX(NASDAQ)

Biopharma long term stock list update: NGSX(NASDAQ) NEUROGESX(NGSX:NASDAQ) and Astellas Enter Commercialization Agreement for Qutenza(TM) MEDX(NASDAQ): up 10% pre mkt.  DNDN(NASDAQ) upgraded   TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER MAPP(NASDAQ) USD 11,3              11          REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,4            LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,2            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           8,5         LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84              83              LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4           6,7              LONG TERM        FDA ANNONCEMENT VICL                 USD 3                 2,5          LONG TERM      SWINE FLU STAA               USD 3,3                   2  LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                      7,65       LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                    53,9    LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                     0,95    LONG TERM         NEXT DATA RELEASE HEB(AMEX)    3,3(5%OF CAPITAL)  2,55         SHORT TERM     AMPLIGEN                                HEB (AMEX) was rebought after 100% gain (see old posts) MRNA(NASDAQ)  3,3                            1,6          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                         11,6        LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             4,6                 LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,6                    LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                    12,1       SHORT TERM KRYSTEXXA APPROVAL NPSP (NASDAQ) 3,1 USD                      4,7                LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                     2,1           LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD             12,3             LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD                          1,55        LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,9      LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD                8,2 PRE MKT.           LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                         9,9             LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,3                         LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6) 26,1                LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)  26,1                        LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)      5,4  6/12 PROFIT TAKING (+35%)

Link articolo originale:
long term biopharma stock list trading-news update:NGSX,MEDX

Biopharma long term stock list update -NGSX(NASDAQ) at 52 weeks high TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER MAPP(NASDAQ) USD 11,3              11,5          REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,5            LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,2            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           8,6         LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84              83,4              LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4           6,8              LONG TERM        FDA ANNONCEMENT VICL                 USD 3                 2,5          LONG TERM      SWINE FLU STAA               USD 3,3                   2  LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                      7,6       LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                    52,8    LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                         1        LONG TERM         NEXT DATA RELEASE HEB(AMEX)    3,3(5%OF CAPITAL)  2,5         SHORT TERM     AMPLIGEN                                HEB (AMEX) was rebought after 100% gain (see old posts) MRNA(NASDAQ)  3,3                            1,6          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                         11,5        LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             4,4                 LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,2                    LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                    12,6       SHORT TERM KRYSTEXXA APPROVAL NPSP (NASDAQ) 3,1 USD                      4,5                LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                     2           LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD             12,3             LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD                          1,3        LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,9      LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD                          7,1           LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                         9,2             LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,3                         LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6) 25,8                LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)  25,8                        LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)      5,4  6/12 PROFIT TAKING (+35%)

Fonte:
trading-news biopharma stock list update

long term trading-news stock list: we are joining – Huge profit taking on AINV(+20%) – We are addding AGN(NYSE), PIR(NYSE), SJM(NYSE) with  more upside in the long term TICKER            BUY AREA         QUOTE NOW           POSITION SJM(NYSE)        43,6                48                   LONG TERM  AGN(NYSE)       45,3                 46,1                LONG TERM  PIR(NYSE)      2,2                       2                LONG TERM LZB(NYSE)       4,6                        4          LONG TERM FDS(NYSE) USD 52,3                   50      LONG TERM STRONG RESULTS ZUMZ(NASDAQ) USD 8,6               8,1          LONG TERM BOTTOMING YHOO(NASDAQ) USD 16,6           15,4        LONG TERM STRONG CONSENSUS CTRN(NASDAQ)  22,8               25,3   HOLD LONG TERM  SHFL(NASDAQ) 5,5                5,4   HOLD LONG TERM NCS(NYSE)      4,05               2,1    HOLD LONG TERM OVERSOLD SAY(NYSE)       3,65            3,7      HOLD LONG TERM MOV(NYSE)         9,5             11,2   HOLD LONG TERM JTX(NYSE)            4,9        7,4 PROFIT TAKED(+50%)            CMTL(NASDAQ) 28,8               30,1   HOLD LONG TERM  GIII(NASDAQ)   9,8                    11   HOLD LONG TERM AINV(NASDAQ)    5,4                  6,4 PROFIT TAKING(+20%)      COT(NYSE)           2,8        PROFIT TAKED(+170%) 5/2(see old posts) TLB(NYSE)            4,6       6/10 PROFIT TAKED 5 (+10%) CPSL(NSDAQ)      3,05                 2,4              HOLD BBI(NYSE)           1,04                  0,8             HOLD THC(NYSE)           2,6                 3         HOLD SKS(NYSE)           3,45            3,9            HOLD SHLD(NASDAQ)      60,6                 6/11  PROFIT TAKED 69,8 (+17%)           VRGY(NASDAQ)    12,6           10,7  HOLD SAFM(NASDAQ)      47           48,5   HOLD PERY(NASDAQ)       8,9           7,8 HOLD LONG TERM

Continua Articolo Originale:
long term stock list trading-news update

  Biopharma long term stock list update TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER MAPP(NASDAQ) USD 11,3              11,4          REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,5            LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,2            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           8,6         LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84              83,4              LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4           6,7              LONG TERM        FDA ANNONCEMENT VICL                 USD 3                 2,5          LONG TERM      SWINE FLU STAA               USD 3,3                   2,1 LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                      7,6       LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                    52    LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                         1        LONG TERM         NEXT DATA RELEASE HEB(AMEX)    3,3(5%OF CAPITAL)  2,4         SHORT TERM     AMPLIGEN                                HEB (AMEX) was rebought after 100% gain (see old posts) MRNA(NASDAQ)  3,3                            1,6          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                         11,5        LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             4,4                 LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,2                    LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                    12,6       SHORT TERM KRYSTEXXA APPROVAL NPSP (NASDAQ) 3,1 USD                      4,5                LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                     2           LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD             12,3             LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD                          1,3        LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,9      LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD                          7,1           LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                         9,2             LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,3                         LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6) 25,8                LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)  25,8                        LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)      5,4  6/12 PROFIT TAKING (+35%)

Prosegue Articolo Originale:
biopharma long term stock lists trading-news update

 SVNT(NASDAQ): 14-1 panel recommendation for Kristeexa approval, tremendus results, target price 15/25 us dollars TICKER    BUY AREA         QUOTE NOW          POSITION                        DRIVERS SVNT  7,1(see old posts)     12,5       SHORT TERM(45 DAYS) KRYSTEEXA PANEL RESULTS                                                                                                                FDA APPROVAL DATE 8/1/09     – STAA(NASDAQ) up 12%: receives japanese clearance for product   TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER MAPP(NASDAQ) USD 11,3              11,3          REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,6            LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,2            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           8,5         LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84              85,2              LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4           6,4               LONG TERM        FDA ANNONCEMENT VICL                 USD 3                           2,5           LONG TERM      SWINE FLU STAA               USD 3,3                    2,1     LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                        8,1       LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                       50,8      LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                          1          LONG TERM         NEXT DATA RELEASE HEB(AMEX)      3,3(5%OF CAPITAL)       2,4               SHORT TERM     AMPLIGEN MRNA(NASDAQ)  3,3                            1,6          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                         11,5         LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             4,3                 LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,2                     LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                    12,4              SHORT TERM KRYSTEXXA NPSP (NASDAQ) 3,1 USD                      4,5                LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                        2,1                     LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD             12,1              LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD                          1,4        LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,8      LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD                          7,1           LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                         9,2             LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,2                         LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6) 25,5                LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)  25,2                        LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)      5,4  6/12 PROFIT TAKING (+35%)

Fonte:
biopharma long term stock lists trading-news update: SVNT, STAA

  – SVNT(NASDAQ): 14-1 panel recommendation for Kristeexa approval, tremendus results, target price 15/25 us dollars TICKER    BUY AREA         QUOTE NOW          POSITION                        DRIVERS SVNT  7,1(see old posts) 12,6 (P.M.) SHORT TERM(45 DAYS) KRYSTEEXA PANEL RESULTS                                                                                                                FDA APPROVAL DATE 8/1/09   – ARRY(NASDAQ) upgraded – STAA(NASDAQ) receive japanese clearance for product   TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER MAPP(NASDAQ) USD 11,3              11,7          REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,7            LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,2            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           8,6         LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84              82,7              LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4           6,4               LONG TERM        FDA ANNONCEMENT VICL                 USD 3                           2,6           LONG TERM      SWINE FLU STAA               USD 3,3                    1,9     LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                        8,2       LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                       50,2      LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                          1          LONG TERM         NEXT DATA RELEASE HEB(AMEX)      3,3(5%OF CAPITAL)       2,6               SHORT TERM     AMPLIGEN MRNA(NASDAQ)  3,3                            1,7          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                         11,4         LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             4,3                  LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,3                     LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                     9,3                 SHORT TERM KRYSTEXXA NPSP (NASDAQ) 3,1 USD                      4,5                LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                        2,1                     LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD                11,9              LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD                          1,6        LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,9      LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD                          7,1           LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                         9             LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,3                         LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6) 25,6                LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)  25,4                         LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)      5,4  6/12 PROFIT TAKING (+35%)

Guarda Articolo Originale:
biopharma long term stock lists trading-news update: SVNT

trading-news is updating biopharma long term stock list, we signal in red recent strong perfomer stock and new position taked: SVNT(NASDAQ): trading halted, news pending ARYX(NASDAQ): stock up 9%         TICKER              BUY AREA              QUOTE NOW     POSITION              DRIVER MAPP(NASDAQ) USD 11,3              11,3          REBUYING LONG TERM STRONG CONSENSUS   ARYX(NASDAQ) USD 4,5                 4,7            LONG TERM           CLINICAL DATA  ARRY(NASDAQ) USD 3,1                 3,2            LONG TERM          CLINICAL DATA  GTXI(NASDAQ)   USD 9,5           8,6         LONG TERM         FDA ANNONCEMENT UTHR(NASDAQ) USD 84              82,3               LONG TERM        FDA ANNONCEMENT NGSX(NASDAQ) USD 6,4           6,4               LONG TERM        FDA ANNONCEMENT VICL                 USD 3                           2,6           LONG TERM      SWINE FLU STAA               USD 3,3                    1,9     LONG TERM   FDA CLEARENCE FOR Epiphany(TM) ALTH(NASDAQ)  7,9                        8,2       LONG TERM          FDA ANNONCEMENT AMAG(NASDAQ) 52,8                       50      LONG TERM        FDA ANNONCEMENT  XOMA(NASDAQ) 1,2                          1          LONG TERM         NEXT DATA RELEASE HEB(AMEX)      3,3(5%OF CAPITAL)       2,6               SHORT TERM     AMPLIGEN MRNA(NASDAQ)  3,3                            1,75          LONG TERM      OVERSOLD RIGL(NASDAQ) USD 10                         11,4         LONG TERM     NEXT DATA RELEASE  MITI(NASDAQ) USD 6                             4,4                  LONG TERM      OVERSOLD MNKD (NASDAQ)  USD 8,3                         8,3                     LONG TERM    AFRESA SVNT (NASDAQ) USD 7,10                     9,3                 SHORT TERM KRYSTEXXA NPSP (NASDAQ) 3,1 USD                      4,6                LONG TERM  STRONG CONSENSUS SCLN (NASDAQ) 2,25 USD                        2,1                     LONG TERM ZADAXIN SALES MAPP (NASDAQ) 8 USD(posts from 5/26)    PROFIT TAKED(+45%)   LEVADEX VNDA (NASDAQ) 8 USD (see old post 5/8)    PROFIT TAKED(+80%)     FANAT CLDA (NASDAQ) 15,7 USD                11,7              LONG TERM   OVERSOLD CTIC (NASDAQ) 2,10 USD                          1,6        LONG TERM PIXANTRONE/OPAXIO RESULTS ANPI (NASDAQ) 2 USD                       1,9      LONG TERM OPTIOM® FDA CLEARENCE MEDX (NASDAQ) 7,5 USD                          7,2           LONG TERM RECENT PRODUCTS RESULTS MNTA (NASDAQ) 8,9 USD                         9             LONG TERM STRONG CONSENSUS ACAD (NASDAQ) 2,6 USD(see old post 5/6) 2,3                         LONG TERM BIOVAIL PACT ACOR (NASDAQ) 24 USD (see old post 5/6) 25,4                LONG TERM FAMPRIDINE-SR BDSI (NASDAQ)                                     PROFIT TAKED 6,3 (+18%)        ONSOLIS DNDN (NASDAQ) 22 USD (see old post 4/27)  25,4                         LONG TERM PROVENGE SPPI (NASDAQ) 4 USD (see ols post 5/12)      5,4  6/12 PROFIT TAKING (+35%)

Articolo completo fonte:
biopharma stock list trading news update

Se, invece, hai altre entrate, sotto forma di rendite di vario tipo (adsense, adwords, affiliazioni, forex , dropship, trading online, investimenti vari, etc), il discorso cambia, e parecchio. E quale strumento migliore di internet per …

Fonte:
Monitor LCD Samsung 19” Widescreen – Sconti e saldi – Gigacenter

Overnight and intraday plays trading-news update: we signal in red data released by OREX(NASDAQ),  AMLN(NASDAQ)and  XOMA(NASDAQ):     TICKER OREX (NASDAQ)   XOMA (NASDAQ)   AMLN (NASDAQ) XTNT (NASDAQ )   ZQK (NYSE)           NCS (NYSE)          GNBT (NASDAQ)  SEAC (NASDAQ) GES (NYSE) HEB (AMEX) HEB  (AMEX)                  BUY AREA           QUOTE NOW                     DRIVER/POSITION USD 4,55                 4,2                http://finance.yahoo.com/news/OrexigenR-… USD1,15                 1,10       http://investors.xoma.com/releasedetail…. USD 11,25              11,1    Once-weekly Amylin drug tops Januvia, Actos-study USD 1,5/1,7                                 SOLD 2,4(+55) USD 3,3                   3,5                               OVER WEEKEND, RESULTS       USD 4,05                 4                                     OVER WEEKEND, RESULTS  USD 0,98                                             SOLD 1 (+2%)       7,9                                                  SOLD7.75 (-2,5%)                                                     27,5                                           SOLD 28,6 (+4%) 2,69                      2,75         REBOUGHT WITH 5%OF CAPITAL   USD 2,15                                       SOLD 4,2(+100%) 

Link fonte:
intraday/over weekend plays trading-news update

Scopriamo cos’è l’indicatore Williams e come può aiutarci a prevedere il trend delle valute nel forex ! … HyperTrader · Info- Investimenti · InvestireOggi · CSI Finanza · Forex per Tutti …

Link articolo originale:
Indicatore Williams Range | Forex Online Trading

Tagged with business, Denaro, emerpas, Euro, forex , Forex trading, forward foreign exchange, guadagnare con i forex , Guadagnare denaro, guadagni facili, investimenti , investimenti forex , Mercati finanziari, Trading online …

Approfondimento fonte:
Trading online:Hai mai provato ad investire sul Forex? Cosa …